ライフサイエンスコーパス: animal test

1 prioritizing chemicals for ED-related whole-animal tests.

2 date compounds are processed in cell-line or animal tests.

3 suming and expensive cell culture assays and animal testing.

4 als has historically been undertaken through animal testing.

5 a, were the most effective means of reducing animal testing.

6 ry pipeline, currently involving large scale animal testing.

7 logical endpoints and mating studies used in animal testing.

8 l chemicals and can also reduce the need for animal testing.

9 e novel drugs and drug combinations prior to animal testing.

10 rP-Sc in these tissues is the basis for live-animal testing.

11 mine the efficacy of lead compounds prior to animal testing.

12 hat differs from all previous cell types and animals tested.

13 gative for all other heterologous plants and animals tested.

14 urrent model, CNV was produced in 95% of the animals tested (19/20).

15 In addition, animals tested 24 h after receiving the lowest dose (0.1

16 rease in CTLp was maintained in five of five animals tested 6 months after transplant.

17 ly evident up to 60 min after PCP injection; animals tested 80 min after injection, when cortical dop

18 ural products should facilitate their use in animal testing and clinical trials.

19 an be applied to future programs to minimize animal testing and promote more human-relevant chemical

20 Social pressure to minimize the use of animal testing and the ever-increasing concern on animal

21 idence of RVF infection was found in 9.2% of animals tested and across 23 districts of Kenya, reflect

22 s antidonor IgG was detected in four of four animals tested, and the 5-day mixed lymphocyte response

23 Despite the potential for extensive animal testing, animal welfare guidelines were not provi

24 AS-MOR rats was profound at 24 and 48 h, but animals tested at 72 h were similar to control groups.

25 However, RH animals tested at acute hypoglycemia ( approximately 2.8

26 blooms and brevetoxin was detected in 52% of animals tested at concentrations up to 500 ng/g.

27 o be met before traditional cell culture and animal testing become obsolete.

28 olony-forming assays was equivalent in all 5 animals tested, but the in vivo levels of mononuclear ce

29 In contrast, in animals tested during adolescence, there was no longer a

30 same behavior was unaffected by SCH 23390 in animals tested during the later stages of training.

31 convenient and cost-effective alternative to animal testing for evaluating the regulation of mammalia

32 a reliable and representative alternative to animal testing for the initial screening of SC formulati

33 LC and NAcc of drug-paired and drug-unpaired animals tested for CPP, we observed no significant diffe

34 Aged animals tested for spontaneous locomotor activity were f

35 native cell system to PHHs, complementary to animal testing, for initial hepatotoxicity screening or

36 nsiderations related to conducting extensive animal testing have resulted in various initiatives to p

37 driven by new legislation, aimed at reducing animal testing in chemical risk assessment but mainly as

38 red to equally experienced and cocaine-naive animals tested in a novel environment.

39 istically in lesioned versus vehicle-treated animals tested in adulthood.

40 reased Ag-specific proliferation in half the animals tested, indicating a suppressive effect of gamma

41 ove towards a future in which less data from animal tests is required in the assessment of chemical s

42 For four of five animals tested, LF exhibited a triphasic kinetic profile

43 Across the animals tested, mean transmission efficiencies of -41.2,

44 eneficial responsiveness to fluoxetine in an animal test of antidepressant efficacy were strongly red

45 ther than behavioral changes in conventional animal tests of depression.

46 sequencing, cloning, gene inactivation, and animal testing offers an efficient, rational, and rigoro

47 Preclinical animal testing often fails to predict adverse outcomes a

48 The high variability and expense of animal testing often makes it unfeasible to examine this

49 f cardiac AC was affected in all alpha i2-/- animals tested, only 50% of the alpha i2-/- animals show

50 show adverse hepatic effects in preclinical animal tests or initial studies in man, it was later wit

51 y occlusion, yet it prevented VF in 10 of 11 animals tested (P<.001).

52 xfoliated cervicovaginal cells from 19 of 54 animals tested positive for at least one PV.

53 Two of eight (25%) animals tested positive from fallopian tube samples.

54 ds (26) was found to have potent activity in animal tests predictive of antipsychotic activity in hum

55 ieve sensitivities comparable to an approved animal testing protocol.

56 vailable for correlating results to approved animal testing protocols.

57 years in residence in the United States, the animal tested serologically positive for B. equi by the

58 Chlorthiazide's toxic dose for 50% of animals tested (TD50) could not be achieved even with do

59 esia but also support the validity of recent animal tests that are thought to capture aspects of epis

60 Surprisingly, in a portion of the animals tested, the BHV-1.1 gE and gI proteins functione

61 In five of the nine animals tested, this slowly-decaying excitation could be

62 was partially suppressed in three-fourths of animals tested three months later, although one animal h

63 shift from primarily relying on traditional animal testing to incorporating advances in biotechnolog

64 -movement analysis could complement existing animal tests to improve preclinical drug development.

65 ) is a trace amine present in the CNS of all animals tested to date.

66 the pre-clinical testing process subject to animal testing upon adaptation in new drug discovery.

67 be MRI safe by in vitro phantom and in vivo animal testing were enrolled.

68 isting information or through new vertebrate animal testing were voluntarily submitted by chemical co

69 Sixteen of 469 tolerant animals tested were found to have developed antidonor an

70 All animals tested were in renal failure, with blood urea ni

71 current hypoglycemia impaired performance in animals tested when hypoglycemic (45 +/- 4 vs. 55 +/- 2%

72 ches are needed that decrease (or eliminate) animal testing while increasing predictivity.

73 Furthermore, on the challenge test, OVX+E animals tested without estrogen treatment continue to ex